Global Anticancer Biologics Market Growth (Status and Outlook) 2026-2032
The global Anticancer Biologics market size is predicted to grow from US$ 109033 million in 2025 to US$ 213624 million in 2032; it is expected to grow at a CAGR of 9.6% from 2026 to 2032.
Anticancer Biologics are a class of biologic medicines that use antibodies, proteins, cells, viruses, or other biologically derived substances as their primary active components to treat cancer through mechanisms such as specifically recognizing tumor-associated targets, modulating immune responses, directly eliminating tumor cells, blocking tumor growth signaling pathways, or altering the tumor microenvironment. Anticancer Biologics mainly include monoclonal antibodies, bispecific and multispecific antibodies, antibody-drug conjugates, cell therapies, cancer vaccines, and oncolytic virus therapies, and are widely used in the treatment of lung cancer, breast cancer, gastrointestinal cancers, hematologic cancers, and other malignant tumors.
Anticancer Biologics represent an important segment of modern cancer therapy and mainly include monoclonal antibodies, bispecific and multispecific antibodies, antibody-drug conjugates, cell therapies, cancer vaccines, and oncolytic virus therapies. Compared with conventional chemotherapy, Anticancer Biologics generally offer greater target specificity, more clearly defined mechanisms of action, and the ability to activate or modulate the immune system. They are widely used in the treatment of lung cancer, breast cancer, gastrointestinal cancers, hematologic cancers, and various other malignancies.
From an industry value-chain perspective, the upstream segment mainly includes cell lines, culture media, single-use bioreactors, chromatography media, filtration materials, pharmaceutical excipients, as well as key materials such as antibodies, payloads, and linkers. The midstream segment covers drug discovery, cell-line development, process development, drug-substance manufacturing, formulation, aseptic filling, quality control, and clinical development. Downstream demand mainly comes from general hospitals, oncology specialty hospitals, hematology treatment centers, and other specialized medical institutions. Antibody-based products are generally manufactured at scale through mammalian cell culture and bioreactor systems, with individual production lines ranging from several thousand liters to tens of thousands of liters in capacity, while cell therapies and cancer vaccines typically rely on smaller-batch, more flexible, and in some cases patient-specific manufacturing models.
The Anticancer Biologics industry is characterized by long development cycles, high technological barriers, stringent regulatory requirements, and substantial capital investment. Manufacturing costs are influenced by cell-culture productivity, protein expression levels, purification yields, raw material costs, production scale, and capacity utilization. Mature antibody products can generally achieve relatively attractive gross margins once large-scale production is established, while cell therapies, complex bispecific antibodies, and certain antibody-drug conjugates tend to carry higher manufacturing costs because of their more complicated production processes, smaller batch sizes, and stricter quality-control requirements. Advances in continuous manufacturing, single-use bioreactors, high-expression cell lines, and automated quality-control technologies are steadily improving manufacturing efficiency across the industry.
The competitive landscape is shaped by both large multinational pharmaceutical companies and biotechnology companies with differentiated technology platforms. Large pharmaceutical companies generally benefit from stronger capabilities in clinical development, global regulatory registration, commercialization, and large-scale manufacturing, while emerging biotechnology companies compete through innovative approaches such as bispecific antibodies, antibody-drug conjugates, cell therapies, and novel immuno-oncology targets. Chinese companies have developed rapidly in areas including PD-1/PD-L1 antibodies, bispecific antibodies, antibody-drug conjugates, and cell therapies, and are increasingly expanding into global markets through licensing agreements, co-development partnerships, and international clinical trials.
Looking forward, the Anticancer Biologics industry is expected to evolve from conventional single-target monoclonal antibodies toward bispecific and multispecific antibodies, next-generation antibody-drug conjugates, cell therapies, and combination treatments involving multiple mechanisms of action. Biomarker-based patient selection, precision treatment, subcutaneous formulations, long-acting formulations, and more efficient manufacturing processes are also expected to become increasingly important sources of clinical and commercial differentiation. As more biologic therapies move from later-line treatment into first-line, neoadjuvant, and adjuvant settings, Anticancer Biologics are expected to play an increasingly important role in the global cancer treatment landscape.
Report Scope
LPI (LP Information)' newest research report, the “Anticancer Biologics Industry Forecast” looks at past sales and reviews total world Anticancer Biologics sales in 2025, providing a comprehensive analysis by region and market sector of projected Anticancer Biologics sales for 2026 through 2032. With Anticancer Biologics sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Anticancer Biologics industry.
This Insight Report provides a comprehensive analysis of the global Anticancer Biologics landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Anticancer Biologics portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Anticancer Biologics market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Anticancer Biologics and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Anticancer Biologics.
This report presents a comprehensive overview, market shares, and growth opportunities of Anticancer Biologics market by product type, application, key players and key regions and countries.
Market Segmentation
Anticancer Biologics are a class of biologic medicines that use antibodies, proteins, cells, viruses, or other biologically derived substances as their primary active components to treat cancer through mechanisms such as specifically recognizing tumor-associated targets, modulating immune responses, directly eliminating tumor cells, blocking tumor growth signaling pathways, or altering the tumor microenvironment. Anticancer Biologics mainly include monoclonal antibodies, bispecific and multispecific antibodies, antibody-drug conjugates, cell therapies, cancer vaccines, and oncolytic virus therapies, and are widely used in the treatment of lung cancer, breast cancer, gastrointestinal cancers, hematologic cancers, and other malignant tumors.
Anticancer Biologics represent an important segment of modern cancer therapy and mainly include monoclonal antibodies, bispecific and multispecific antibodies, antibody-drug conjugates, cell therapies, cancer vaccines, and oncolytic virus therapies. Compared with conventional chemotherapy, Anticancer Biologics generally offer greater target specificity, more clearly defined mechanisms of action, and the ability to activate or modulate the immune system. They are widely used in the treatment of lung cancer, breast cancer, gastrointestinal cancers, hematologic cancers, and various other malignancies.
From an industry value-chain perspective, the upstream segment mainly includes cell lines, culture media, single-use bioreactors, chromatography media, filtration materials, pharmaceutical excipients, as well as key materials such as antibodies, payloads, and linkers. The midstream segment covers drug discovery, cell-line development, process development, drug-substance manufacturing, formulation, aseptic filling, quality control, and clinical development. Downstream demand mainly comes from general hospitals, oncology specialty hospitals, hematology treatment centers, and other specialized medical institutions. Antibody-based products are generally manufactured at scale through mammalian cell culture and bioreactor systems, with individual production lines ranging from several thousand liters to tens of thousands of liters in capacity, while cell therapies and cancer vaccines typically rely on smaller-batch, more flexible, and in some cases patient-specific manufacturing models.
The Anticancer Biologics industry is characterized by long development cycles, high technological barriers, stringent regulatory requirements, and substantial capital investment. Manufacturing costs are influenced by cell-culture productivity, protein expression levels, purification yields, raw material costs, production scale, and capacity utilization. Mature antibody products can generally achieve relatively attractive gross margins once large-scale production is established, while cell therapies, complex bispecific antibodies, and certain antibody-drug conjugates tend to carry higher manufacturing costs because of their more complicated production processes, smaller batch sizes, and stricter quality-control requirements. Advances in continuous manufacturing, single-use bioreactors, high-expression cell lines, and automated quality-control technologies are steadily improving manufacturing efficiency across the industry.
The competitive landscape is shaped by both large multinational pharmaceutical companies and biotechnology companies with differentiated technology platforms. Large pharmaceutical companies generally benefit from stronger capabilities in clinical development, global regulatory registration, commercialization, and large-scale manufacturing, while emerging biotechnology companies compete through innovative approaches such as bispecific antibodies, antibody-drug conjugates, cell therapies, and novel immuno-oncology targets. Chinese companies have developed rapidly in areas including PD-1/PD-L1 antibodies, bispecific antibodies, antibody-drug conjugates, and cell therapies, and are increasingly expanding into global markets through licensing agreements, co-development partnerships, and international clinical trials.
Looking forward, the Anticancer Biologics industry is expected to evolve from conventional single-target monoclonal antibodies toward bispecific and multispecific antibodies, next-generation antibody-drug conjugates, cell therapies, and combination treatments involving multiple mechanisms of action. Biomarker-based patient selection, precision treatment, subcutaneous formulations, long-acting formulations, and more efficient manufacturing processes are also expected to become increasingly important sources of clinical and commercial differentiation. As more biologic therapies move from later-line treatment into first-line, neoadjuvant, and adjuvant settings, Anticancer Biologics are expected to play an increasingly important role in the global cancer treatment landscape.
Report Scope
LPI (LP Information)' newest research report, the “Anticancer Biologics Industry Forecast” looks at past sales and reviews total world Anticancer Biologics sales in 2025, providing a comprehensive analysis by region and market sector of projected Anticancer Biologics sales for 2026 through 2032. With Anticancer Biologics sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Anticancer Biologics industry.
This Insight Report provides a comprehensive analysis of the global Anticancer Biologics landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Anticancer Biologics portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Anticancer Biologics market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Anticancer Biologics and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Anticancer Biologics.
This report presents a comprehensive overview, market shares, and growth opportunities of Anticancer Biologics market by product type, application, key players and key regions and countries.
Market Segmentation
Segmentation by Type:
- Antibody Therapies
- Antibody-Drug Conjugates (ADCs)
- Cell Therapies
- Cancer Vaccines and Oncolytic Viruses
- Others
Segmentation by Target:
- Immune Checkpoint Targets
- Solid Tumor-Associated Targets
- Hematologic Tumor Targets
- Angiogenesis-Related Targets
- Others
Segmentation by Route of Administration:
- Intravenous Administration
- Subcutaneous Administration
- Cell Infusion
- Intratumoral Administration
- Others
Segmentation by Application:
- Lung Cancer
- Breast Cancer
- Hematologic Cancers
- Gastrointestinal Cancers
- Others
This report also splits the market by region:
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- AbbVie Inc.
- Johnson & Johnson
- Novartis AG
- Gilead Sciences, Inc.
- Roche Holding AG
- Bristol-Myers Squibb Company
- Amgen Inc.
- AstraZeneca plc
- Merck & Co., Inc.
- Takeda Pharmaceutical Company Limited
- Merck KGaA
- Eli Lilly and Company
- Ono Pharmaceutical Co., Ltd.
- Pfizer Inc.
- GSK plc
- Regeneron Pharmaceuticals, Inc.
- Innovent Biologics, Inc.
- Jiangsu Hengrui Pharmaceuticals Co., Ltd.
- Shanghai Junshi Biosciences Co., Ltd.
- Akeso, Inc.
- Shanghai Henlius Biotech, Inc.
- RemeGen Co., Ltd.
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
- Sino Biopharmaceutical Limited
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
- Jiangsu Alphamab Biopharmaceuticals Co., Ltd.
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Anticancer Biologics Market Size (2021-2032)
2.1.2 Anticancer Biologics Market Size CAGR by Region (2021 VS 2025 VS 2032)
2.1.3 World Current & Future Analysis for Anticancer Biologics by Country/Region (2021, 2025 & 2032)
2.2 Anticancer Biologics Segment by Type
2.2.1 Antibody Therapies
2.2.2 Antibody-Drug Conjugates (ADCs)
2.2.3 Cell Therapies
2.2.4 Cancer Vaccines and Oncolytic Viruses
2.2.5 Others
2.2.6 Anticancer Biologics Market Size by Type
2.2.6.1 Anticancer Biologics Market Size CAGR by Type (2021 VS 2025 VS 2032)
2.2.6.2 Global Anticancer Biologics Market Size Market Share by Type (2021-2026)
2.3 Anticancer Biologics Segment by Target
2.3.1 Immune Checkpoint Targets
2.3.2 Solid Tumor-Associated Targets
2.3.3 Hematologic Tumor Targets
2.3.4 Angiogenesis-Related Targets
2.3.5 Others
2.3.6 Anticancer Biologics Market Size by Target
2.3.6.1 Anticancer Biologics Market Size CAGR by Target (2021 VS 2025 VS 2032)
2.3.6.2 Global Anticancer Biologics Market Size Market Share by Target (2021-2026)
2.4 Anticancer Biologics Segment by Route of Administration
2.4.1 Intravenous Administration
2.4.2 Subcutaneous Administration
2.4.3 Cell Infusion
2.4.4 Intratumoral Administration
2.4.5 Others
2.4.6 Anticancer Biologics Market Size by Route of Administration
2.4.6.1 Anticancer Biologics Market Size CAGR by Route of Administration (2021 VS 2025 VS 2032)
2.4.6.2 Global Anticancer Biologics Market Size Market Share by Route of Administration (2021-2026)
2.5 Anticancer Biologics Segment by Application
2.5.1 Lung Cancer
2.5.2 Breast Cancer
2.5.3 Hematologic Cancers
2.5.4 Gastrointestinal Cancers
2.5.5 Others
2.5.6 Anticancer Biologics Market Size by Application
2.5.6.1 Anticancer Biologics Market Size CAGR by Application (2021 VS 2025 VS 2032)
2.5.6.2 Global Anticancer Biologics Market Size Market Share by Application (2021-2026)
3 ANTICANCER BIOLOGICS MARKET SIZE BY PLAYER
3.1 Anticancer Biologics Market Size Market Share by Player
3.1.1 Global Anticancer Biologics Revenue by Player (2021-2026)
3.1.2 Global Anticancer Biologics Revenue Market Share by Player (2021-2026)
3.2 Global Anticancer Biologics Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 ANTICANCER BIOLOGICS BY REGION
4.1 Anticancer Biologics Market Size by Region (2021-2026)
4.2 Global Anticancer Biologics Annual Revenue by Country/Region (2021-2026)
4.3 Americas Anticancer Biologics Market Size Growth (2021-2026)
4.4 APAC Anticancer Biologics Market Size Growth (2021-2026)
4.5 Europe Anticancer Biologics Market Size Growth (2021-2026)
4.6 Middle East & Africa Anticancer Biologics Market Size Growth (2021-2026)
5 AMERICAS
5.1 Americas Anticancer Biologics Market Size by Country (2021-2026)
5.2 Americas Anticancer Biologics Market Size by Type (2021-2026)
5.3 Americas Anticancer Biologics Market Size by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Anticancer Biologics Market Size by Region (2021-2026)
6.2 APAC Anticancer Biologics Market Size by Type (2021-2026)
6.3 APAC Anticancer Biologics Market Size by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Anticancer Biologics Market Size by Country (2021-2026)
7.2 Europe Anticancer Biologics Market Size by Type (2021-2026)
7.3 Europe Anticancer Biologics Market Size by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Anticancer Biologics by Region (2021-2026)
8.2 Middle East & Africa Anticancer Biologics Market Size by Type (2021-2026)
8.3 Middle East & Africa Anticancer Biologics Market Size by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL ANTICANCER BIOLOGICS MARKET FORECAST
10.1 Global Anticancer Biologics Forecast by Region (2027-2032)
10.1.1 Global Anticancer Biologics Forecast by Region (2027-2032)
10.1.2 Americas Anticancer Biologics Forecast
10.1.3 APAC Anticancer Biologics Forecast
10.1.4 Europe Anticancer Biologics Forecast
10.1.5 Middle East & Africa Anticancer Biologics Forecast
10.2 Americas Anticancer Biologics Forecast by Country (2027-2032)
10.2.1 United States Market Anticancer Biologics Forecast
10.2.2 Canada Market Anticancer Biologics Forecast
10.2.3 Mexico Market Anticancer Biologics Forecast
10.2.4 Brazil Market Anticancer Biologics Forecast
10.3 APAC Anticancer Biologics Forecast by Region (2027-2032)
10.3.1 China Anticancer Biologics Market Forecast
10.3.2 Japan Market Anticancer Biologics Forecast
10.3.3 Korea Market Anticancer Biologics Forecast
10.3.4 Southeast Asia Market Anticancer Biologics Forecast
10.3.5 India Market Anticancer Biologics Forecast
10.3.6 Australia Market Anticancer Biologics Forecast
10.4 Europe Anticancer Biologics Forecast by Country (2027-2032)
10.4.1 Germany Market Anticancer Biologics Forecast
10.4.2 France Market Anticancer Biologics Forecast
10.4.3 UK Market Anticancer Biologics Forecast
10.4.4 Italy Market Anticancer Biologics Forecast
10.4.5 Russia Market Anticancer Biologics Forecast
10.5 Middle East & Africa Anticancer Biologics Forecast by Region (2027-2032)
10.5.1 Egypt Market Anticancer Biologics Forecast
10.5.2 South Africa Market Anticancer Biologics Forecast
10.5.3 Israel Market Anticancer Biologics Forecast
10.5.4 Turkey Market Anticancer Biologics Forecast
10.6 Global Anticancer Biologics Forecast by Type (2027-2032)
10.7 Global Anticancer Biologics Forecast by Application (2027-2032)
10.7.1 GCC Countries Market Anticancer Biologics Forecast
11 KEY PLAYERS ANALYSIS
11.1 AbbVie Inc.
11.1.1 AbbVie Inc. Company Information
11.1.2 AbbVie Inc. Anticancer Biologics Product Offered
11.1.3 AbbVie Inc. Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026)
11.1.4 AbbVie Inc. Main Business Overview
11.1.5 AbbVie Inc. Latest Developments
11.2 Johnson & Johnson
11.2.1 Johnson & Johnson Company Information
11.2.2 Johnson & Johnson Anticancer Biologics Product Offered
11.2.3 Johnson & Johnson Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026)
11.2.4 Johnson & Johnson Main Business Overview
11.2.5 Johnson & Johnson Latest Developments
11.3 Novartis AG
11.3.1 Novartis AG Company Information
11.3.2 Novartis AG Anticancer Biologics Product Offered
11.3.3 Novartis AG Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026)
11.3.4 Novartis AG Main Business Overview
11.3.5 Novartis AG Latest Developments
11.4 Gilead Sciences, Inc.
11.4.1 Gilead Sciences, Inc. Company Information
11.4.2 Gilead Sciences, Inc. Anticancer Biologics Product Offered
11.4.3 Gilead Sciences, Inc. Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026)
11.4.4 Gilead Sciences, Inc. Main Business Overview
11.4.5 Gilead Sciences, Inc. Latest Developments
11.5 Roche Holding AG
11.5.1 Roche Holding AG Company Information
11.5.2 Roche Holding AG Anticancer Biologics Product Offered
11.5.3 Roche Holding AG Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026)
11.5.4 Roche Holding AG Main Business Overview
11.5.5 Roche Holding AG Latest Developments
11.6 Bristol-Myers Squibb Company
11.6.1 Bristol-Myers Squibb Company Company Information
11.6.2 Bristol-Myers Squibb Company Anticancer Biologics Product Offered
11.6.3 Bristol-Myers Squibb Company Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026)
11.6.4 Bristol-Myers Squibb Company Main Business Overview
11.6.5 Bristol-Myers Squibb Company Latest Developments
11.7 Amgen Inc.
11.7.1 Amgen Inc. Company Information
11.7.2 Amgen Inc. Anticancer Biologics Product Offered
11.7.3 Amgen Inc. Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026)
11.7.4 Amgen Inc. Main Business Overview
11.7.5 Amgen Inc. Latest Developments
11.8 AstraZeneca plc
11.8.1 AstraZeneca plc Company Information
11.8.2 AstraZeneca plc Anticancer Biologics Product Offered
11.8.3 AstraZeneca plc Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026)
11.8.4 AstraZeneca plc Main Business Overview
11.8.5 AstraZeneca plc Latest Developments
11.9 Merck & Co., Inc.
11.9.1 Merck & Co., Inc. Company Information
11.9.2 Merck & Co., Inc. Anticancer Biologics Product Offered
11.9.3 Merck & Co., Inc. Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026)
11.9.4 Merck & Co., Inc. Main Business Overview
11.9.5 Merck & Co., Inc. Latest Developments
11.10 Takeda Pharmaceutical Company Limited
11.10.1 Takeda Pharmaceutical Company Limited Company Information
11.10.2 Takeda Pharmaceutical Company Limited Anticancer Biologics Product Offered
11.10.3 Takeda Pharmaceutical Company Limited Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026)
11.10.4 Takeda Pharmaceutical Company Limited Main Business Overview
11.10.5 Takeda Pharmaceutical Company Limited Latest Developments
11.11 Merck KGaA
11.11.1 Merck KGaA Company Information
11.11.2 Merck KGaA Anticancer Biologics Product Offered
11.11.3 Merck KGaA Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026)
11.11.4 Merck KGaA Main Business Overview
11.11.5 Merck KGaA Latest Developments
11.12 Eli Lilly and Company
11.12.1 Eli Lilly and Company Company Information
11.12.2 Eli Lilly and Company Anticancer Biologics Product Offered
11.12.3 Eli Lilly and Company Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026)
11.12.4 Eli Lilly and Company Main Business Overview
11.12.5 Eli Lilly and Company Latest Developments
11.13 Ono Pharmaceutical Co., Ltd.
11.13.1 Ono Pharmaceutical Co., Ltd. Company Information
11.13.2 Ono Pharmaceutical Co., Ltd. Anticancer Biologics Product Offered
11.13.3 Ono Pharmaceutical Co., Ltd. Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026)
11.13.4 Ono Pharmaceutical Co., Ltd. Main Business Overview
11.13.5 Ono Pharmaceutical Co., Ltd. Latest Developments
11.14 Pfizer Inc.
11.14.1 Pfizer Inc. Company Information
11.14.2 Pfizer Inc. Anticancer Biologics Product Offered
11.14.3 Pfizer Inc. Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026)
11.14.4 Pfizer Inc. Main Business Overview
11.14.5 Pfizer Inc. Latest Developments
11.15 GSK plc
11.15.1 GSK plc Company Information
11.15.2 GSK plc Anticancer Biologics Product Offered
11.15.3 GSK plc Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026)
11.15.4 GSK plc Main Business Overview
11.15.5 GSK plc Latest Developments
11.16 Regeneron Pharmaceuticals, Inc.
11.16.1 Regeneron Pharmaceuticals, Inc. Company Information
11.16.2 Regeneron Pharmaceuticals, Inc. Anticancer Biologics Product Offered
11.16.3 Regeneron Pharmaceuticals, Inc. Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026)
11.16.4 Regeneron Pharmaceuticals, Inc. Main Business Overview
11.16.5 Regeneron Pharmaceuticals, Inc. Latest Developments
11.17 Innovent Biologics, Inc.
11.17.1 Innovent Biologics, Inc. Company Information
11.17.2 Innovent Biologics, Inc. Anticancer Biologics Product Offered
11.17.3 Innovent Biologics, Inc. Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026)
11.17.4 Innovent Biologics, Inc. Main Business Overview
11.17.5 Innovent Biologics, Inc. Latest Developments
11.18 Jiangsu Hengrui Pharmaceuticals Co., Ltd.
11.18.1 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Company Information
11.18.2 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Anticancer Biologics Product Offered
11.18.3 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026)
11.18.4 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Main Business Overview
11.18.5 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Latest Developments
11.19 Shanghai Junshi Biosciences Co., Ltd.
11.19.1 Shanghai Junshi Biosciences Co., Ltd. Company Information
11.19.2 Shanghai Junshi Biosciences Co., Ltd. Anticancer Biologics Product Offered
11.19.3 Shanghai Junshi Biosciences Co., Ltd. Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026)
11.19.4 Shanghai Junshi Biosciences Co., Ltd. Main Business Overview
11.19.5 Shanghai Junshi Biosciences Co., Ltd. Latest Developments
11.20 Akeso, Inc.
11.20.1 Akeso, Inc. Company Information
11.20.2 Akeso, Inc. Anticancer Biologics Product Offered
11.20.3 Akeso, Inc. Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026)
11.20.4 Akeso, Inc. Main Business Overview
11.20.5 Akeso, Inc. Latest Developments
11.21 Shanghai Henlius Biotech, Inc.
11.21.1 Shanghai Henlius Biotech, Inc. Company Information
11.21.2 Shanghai Henlius Biotech, Inc. Anticancer Biologics Product Offered
11.21.3 Shanghai Henlius Biotech, Inc. Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026)
11.21.4 Shanghai Henlius Biotech, Inc. Main Business Overview
11.21.5 Shanghai Henlius Biotech, Inc. Latest Developments
11.22 RemeGen Co., Ltd.
11.22.1 RemeGen Co., Ltd. Company Information
11.22.2 RemeGen Co., Ltd. Anticancer Biologics Product Offered
11.22.3 RemeGen Co., Ltd. Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026)
11.22.4 RemeGen Co., Ltd. Main Business Overview
11.22.5 RemeGen Co., Ltd. Latest Developments
11.23 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
11.23.1 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Company Information
11.23.2 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Anticancer Biologics Product Offered
11.23.3 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026)
11.23.4 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Main Business Overview
11.23.5 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Latest Developments
11.24 Sino Biopharmaceutical Limited
11.24.1 Sino Biopharmaceutical Limited Company Information
11.24.2 Sino Biopharmaceutical Limited Anticancer Biologics Product Offered
11.24.3 Sino Biopharmaceutical Limited Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026)
11.24.4 Sino Biopharmaceutical Limited Main Business Overview
11.24.5 Sino Biopharmaceutical Limited Latest Developments
11.25 Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
11.25.1 Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. Company Information
11.25.2 Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. Anticancer Biologics Product Offered
11.25.3 Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026)
11.25.4 Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. Main Business Overview
11.25.5 Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. Latest Developments
11.26 Jiangsu Alphamab Biopharmaceuticals Co., Ltd.
11.26.1 Jiangsu Alphamab Biopharmaceuticals Co., Ltd. Company Information
11.26.2 Jiangsu Alphamab Biopharmaceuticals Co., Ltd. Anticancer Biologics Product Offered
11.26.3 Jiangsu Alphamab Biopharmaceuticals Co., Ltd. Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026)
11.26.4 Jiangsu Alphamab Biopharmaceuticals Co., Ltd. Main Business Overview
11.26.5 Jiangsu Alphamab Biopharmaceuticals Co., Ltd. Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Anticancer Biologics Market Size (2021-2032)
2.1.2 Anticancer Biologics Market Size CAGR by Region (2021 VS 2025 VS 2032)
2.1.3 World Current & Future Analysis for Anticancer Biologics by Country/Region (2021, 2025 & 2032)
2.2 Anticancer Biologics Segment by Type
2.2.1 Antibody Therapies
2.2.2 Antibody-Drug Conjugates (ADCs)
2.2.3 Cell Therapies
2.2.4 Cancer Vaccines and Oncolytic Viruses
2.2.5 Others
2.2.6 Anticancer Biologics Market Size by Type
2.2.6.1 Anticancer Biologics Market Size CAGR by Type (2021 VS 2025 VS 2032)
2.2.6.2 Global Anticancer Biologics Market Size Market Share by Type (2021-2026)
2.3 Anticancer Biologics Segment by Target
2.3.1 Immune Checkpoint Targets
2.3.2 Solid Tumor-Associated Targets
2.3.3 Hematologic Tumor Targets
2.3.4 Angiogenesis-Related Targets
2.3.5 Others
2.3.6 Anticancer Biologics Market Size by Target
2.3.6.1 Anticancer Biologics Market Size CAGR by Target (2021 VS 2025 VS 2032)
2.3.6.2 Global Anticancer Biologics Market Size Market Share by Target (2021-2026)
2.4 Anticancer Biologics Segment by Route of Administration
2.4.1 Intravenous Administration
2.4.2 Subcutaneous Administration
2.4.3 Cell Infusion
2.4.4 Intratumoral Administration
2.4.5 Others
2.4.6 Anticancer Biologics Market Size by Route of Administration
2.4.6.1 Anticancer Biologics Market Size CAGR by Route of Administration (2021 VS 2025 VS 2032)
2.4.6.2 Global Anticancer Biologics Market Size Market Share by Route of Administration (2021-2026)
2.5 Anticancer Biologics Segment by Application
2.5.1 Lung Cancer
2.5.2 Breast Cancer
2.5.3 Hematologic Cancers
2.5.4 Gastrointestinal Cancers
2.5.5 Others
2.5.6 Anticancer Biologics Market Size by Application
2.5.6.1 Anticancer Biologics Market Size CAGR by Application (2021 VS 2025 VS 2032)
2.5.6.2 Global Anticancer Biologics Market Size Market Share by Application (2021-2026)
3 ANTICANCER BIOLOGICS MARKET SIZE BY PLAYER
3.1 Anticancer Biologics Market Size Market Share by Player
3.1.1 Global Anticancer Biologics Revenue by Player (2021-2026)
3.1.2 Global Anticancer Biologics Revenue Market Share by Player (2021-2026)
3.2 Global Anticancer Biologics Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 ANTICANCER BIOLOGICS BY REGION
4.1 Anticancer Biologics Market Size by Region (2021-2026)
4.2 Global Anticancer Biologics Annual Revenue by Country/Region (2021-2026)
4.3 Americas Anticancer Biologics Market Size Growth (2021-2026)
4.4 APAC Anticancer Biologics Market Size Growth (2021-2026)
4.5 Europe Anticancer Biologics Market Size Growth (2021-2026)
4.6 Middle East & Africa Anticancer Biologics Market Size Growth (2021-2026)
5 AMERICAS
5.1 Americas Anticancer Biologics Market Size by Country (2021-2026)
5.2 Americas Anticancer Biologics Market Size by Type (2021-2026)
5.3 Americas Anticancer Biologics Market Size by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Anticancer Biologics Market Size by Region (2021-2026)
6.2 APAC Anticancer Biologics Market Size by Type (2021-2026)
6.3 APAC Anticancer Biologics Market Size by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Anticancer Biologics Market Size by Country (2021-2026)
7.2 Europe Anticancer Biologics Market Size by Type (2021-2026)
7.3 Europe Anticancer Biologics Market Size by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Anticancer Biologics by Region (2021-2026)
8.2 Middle East & Africa Anticancer Biologics Market Size by Type (2021-2026)
8.3 Middle East & Africa Anticancer Biologics Market Size by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL ANTICANCER BIOLOGICS MARKET FORECAST
10.1 Global Anticancer Biologics Forecast by Region (2027-2032)
10.1.1 Global Anticancer Biologics Forecast by Region (2027-2032)
10.1.2 Americas Anticancer Biologics Forecast
10.1.3 APAC Anticancer Biologics Forecast
10.1.4 Europe Anticancer Biologics Forecast
10.1.5 Middle East & Africa Anticancer Biologics Forecast
10.2 Americas Anticancer Biologics Forecast by Country (2027-2032)
10.2.1 United States Market Anticancer Biologics Forecast
10.2.2 Canada Market Anticancer Biologics Forecast
10.2.3 Mexico Market Anticancer Biologics Forecast
10.2.4 Brazil Market Anticancer Biologics Forecast
10.3 APAC Anticancer Biologics Forecast by Region (2027-2032)
10.3.1 China Anticancer Biologics Market Forecast
10.3.2 Japan Market Anticancer Biologics Forecast
10.3.3 Korea Market Anticancer Biologics Forecast
10.3.4 Southeast Asia Market Anticancer Biologics Forecast
10.3.5 India Market Anticancer Biologics Forecast
10.3.6 Australia Market Anticancer Biologics Forecast
10.4 Europe Anticancer Biologics Forecast by Country (2027-2032)
10.4.1 Germany Market Anticancer Biologics Forecast
10.4.2 France Market Anticancer Biologics Forecast
10.4.3 UK Market Anticancer Biologics Forecast
10.4.4 Italy Market Anticancer Biologics Forecast
10.4.5 Russia Market Anticancer Biologics Forecast
10.5 Middle East & Africa Anticancer Biologics Forecast by Region (2027-2032)
10.5.1 Egypt Market Anticancer Biologics Forecast
10.5.2 South Africa Market Anticancer Biologics Forecast
10.5.3 Israel Market Anticancer Biologics Forecast
10.5.4 Turkey Market Anticancer Biologics Forecast
10.6 Global Anticancer Biologics Forecast by Type (2027-2032)
10.7 Global Anticancer Biologics Forecast by Application (2027-2032)
10.7.1 GCC Countries Market Anticancer Biologics Forecast
11 KEY PLAYERS ANALYSIS
11.1 AbbVie Inc.
11.1.1 AbbVie Inc. Company Information
11.1.2 AbbVie Inc. Anticancer Biologics Product Offered
11.1.3 AbbVie Inc. Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026)
11.1.4 AbbVie Inc. Main Business Overview
11.1.5 AbbVie Inc. Latest Developments
11.2 Johnson & Johnson
11.2.1 Johnson & Johnson Company Information
11.2.2 Johnson & Johnson Anticancer Biologics Product Offered
11.2.3 Johnson & Johnson Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026)
11.2.4 Johnson & Johnson Main Business Overview
11.2.5 Johnson & Johnson Latest Developments
11.3 Novartis AG
11.3.1 Novartis AG Company Information
11.3.2 Novartis AG Anticancer Biologics Product Offered
11.3.3 Novartis AG Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026)
11.3.4 Novartis AG Main Business Overview
11.3.5 Novartis AG Latest Developments
11.4 Gilead Sciences, Inc.
11.4.1 Gilead Sciences, Inc. Company Information
11.4.2 Gilead Sciences, Inc. Anticancer Biologics Product Offered
11.4.3 Gilead Sciences, Inc. Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026)
11.4.4 Gilead Sciences, Inc. Main Business Overview
11.4.5 Gilead Sciences, Inc. Latest Developments
11.5 Roche Holding AG
11.5.1 Roche Holding AG Company Information
11.5.2 Roche Holding AG Anticancer Biologics Product Offered
11.5.3 Roche Holding AG Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026)
11.5.4 Roche Holding AG Main Business Overview
11.5.5 Roche Holding AG Latest Developments
11.6 Bristol-Myers Squibb Company
11.6.1 Bristol-Myers Squibb Company Company Information
11.6.2 Bristol-Myers Squibb Company Anticancer Biologics Product Offered
11.6.3 Bristol-Myers Squibb Company Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026)
11.6.4 Bristol-Myers Squibb Company Main Business Overview
11.6.5 Bristol-Myers Squibb Company Latest Developments
11.7 Amgen Inc.
11.7.1 Amgen Inc. Company Information
11.7.2 Amgen Inc. Anticancer Biologics Product Offered
11.7.3 Amgen Inc. Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026)
11.7.4 Amgen Inc. Main Business Overview
11.7.5 Amgen Inc. Latest Developments
11.8 AstraZeneca plc
11.8.1 AstraZeneca plc Company Information
11.8.2 AstraZeneca plc Anticancer Biologics Product Offered
11.8.3 AstraZeneca plc Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026)
11.8.4 AstraZeneca plc Main Business Overview
11.8.5 AstraZeneca plc Latest Developments
11.9 Merck & Co., Inc.
11.9.1 Merck & Co., Inc. Company Information
11.9.2 Merck & Co., Inc. Anticancer Biologics Product Offered
11.9.3 Merck & Co., Inc. Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026)
11.9.4 Merck & Co., Inc. Main Business Overview
11.9.5 Merck & Co., Inc. Latest Developments
11.10 Takeda Pharmaceutical Company Limited
11.10.1 Takeda Pharmaceutical Company Limited Company Information
11.10.2 Takeda Pharmaceutical Company Limited Anticancer Biologics Product Offered
11.10.3 Takeda Pharmaceutical Company Limited Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026)
11.10.4 Takeda Pharmaceutical Company Limited Main Business Overview
11.10.5 Takeda Pharmaceutical Company Limited Latest Developments
11.11 Merck KGaA
11.11.1 Merck KGaA Company Information
11.11.2 Merck KGaA Anticancer Biologics Product Offered
11.11.3 Merck KGaA Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026)
11.11.4 Merck KGaA Main Business Overview
11.11.5 Merck KGaA Latest Developments
11.12 Eli Lilly and Company
11.12.1 Eli Lilly and Company Company Information
11.12.2 Eli Lilly and Company Anticancer Biologics Product Offered
11.12.3 Eli Lilly and Company Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026)
11.12.4 Eli Lilly and Company Main Business Overview
11.12.5 Eli Lilly and Company Latest Developments
11.13 Ono Pharmaceutical Co., Ltd.
11.13.1 Ono Pharmaceutical Co., Ltd. Company Information
11.13.2 Ono Pharmaceutical Co., Ltd. Anticancer Biologics Product Offered
11.13.3 Ono Pharmaceutical Co., Ltd. Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026)
11.13.4 Ono Pharmaceutical Co., Ltd. Main Business Overview
11.13.5 Ono Pharmaceutical Co., Ltd. Latest Developments
11.14 Pfizer Inc.
11.14.1 Pfizer Inc. Company Information
11.14.2 Pfizer Inc. Anticancer Biologics Product Offered
11.14.3 Pfizer Inc. Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026)
11.14.4 Pfizer Inc. Main Business Overview
11.14.5 Pfizer Inc. Latest Developments
11.15 GSK plc
11.15.1 GSK plc Company Information
11.15.2 GSK plc Anticancer Biologics Product Offered
11.15.3 GSK plc Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026)
11.15.4 GSK plc Main Business Overview
11.15.5 GSK plc Latest Developments
11.16 Regeneron Pharmaceuticals, Inc.
11.16.1 Regeneron Pharmaceuticals, Inc. Company Information
11.16.2 Regeneron Pharmaceuticals, Inc. Anticancer Biologics Product Offered
11.16.3 Regeneron Pharmaceuticals, Inc. Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026)
11.16.4 Regeneron Pharmaceuticals, Inc. Main Business Overview
11.16.5 Regeneron Pharmaceuticals, Inc. Latest Developments
11.17 Innovent Biologics, Inc.
11.17.1 Innovent Biologics, Inc. Company Information
11.17.2 Innovent Biologics, Inc. Anticancer Biologics Product Offered
11.17.3 Innovent Biologics, Inc. Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026)
11.17.4 Innovent Biologics, Inc. Main Business Overview
11.17.5 Innovent Biologics, Inc. Latest Developments
11.18 Jiangsu Hengrui Pharmaceuticals Co., Ltd.
11.18.1 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Company Information
11.18.2 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Anticancer Biologics Product Offered
11.18.3 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026)
11.18.4 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Main Business Overview
11.18.5 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Latest Developments
11.19 Shanghai Junshi Biosciences Co., Ltd.
11.19.1 Shanghai Junshi Biosciences Co., Ltd. Company Information
11.19.2 Shanghai Junshi Biosciences Co., Ltd. Anticancer Biologics Product Offered
11.19.3 Shanghai Junshi Biosciences Co., Ltd. Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026)
11.19.4 Shanghai Junshi Biosciences Co., Ltd. Main Business Overview
11.19.5 Shanghai Junshi Biosciences Co., Ltd. Latest Developments
11.20 Akeso, Inc.
11.20.1 Akeso, Inc. Company Information
11.20.2 Akeso, Inc. Anticancer Biologics Product Offered
11.20.3 Akeso, Inc. Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026)
11.20.4 Akeso, Inc. Main Business Overview
11.20.5 Akeso, Inc. Latest Developments
11.21 Shanghai Henlius Biotech, Inc.
11.21.1 Shanghai Henlius Biotech, Inc. Company Information
11.21.2 Shanghai Henlius Biotech, Inc. Anticancer Biologics Product Offered
11.21.3 Shanghai Henlius Biotech, Inc. Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026)
11.21.4 Shanghai Henlius Biotech, Inc. Main Business Overview
11.21.5 Shanghai Henlius Biotech, Inc. Latest Developments
11.22 RemeGen Co., Ltd.
11.22.1 RemeGen Co., Ltd. Company Information
11.22.2 RemeGen Co., Ltd. Anticancer Biologics Product Offered
11.22.3 RemeGen Co., Ltd. Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026)
11.22.4 RemeGen Co., Ltd. Main Business Overview
11.22.5 RemeGen Co., Ltd. Latest Developments
11.23 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
11.23.1 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Company Information
11.23.2 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Anticancer Biologics Product Offered
11.23.3 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026)
11.23.4 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Main Business Overview
11.23.5 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Latest Developments
11.24 Sino Biopharmaceutical Limited
11.24.1 Sino Biopharmaceutical Limited Company Information
11.24.2 Sino Biopharmaceutical Limited Anticancer Biologics Product Offered
11.24.3 Sino Biopharmaceutical Limited Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026)
11.24.4 Sino Biopharmaceutical Limited Main Business Overview
11.24.5 Sino Biopharmaceutical Limited Latest Developments
11.25 Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
11.25.1 Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. Company Information
11.25.2 Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. Anticancer Biologics Product Offered
11.25.3 Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026)
11.25.4 Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. Main Business Overview
11.25.5 Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. Latest Developments
11.26 Jiangsu Alphamab Biopharmaceuticals Co., Ltd.
11.26.1 Jiangsu Alphamab Biopharmaceuticals Co., Ltd. Company Information
11.26.2 Jiangsu Alphamab Biopharmaceuticals Co., Ltd. Anticancer Biologics Product Offered
11.26.3 Jiangsu Alphamab Biopharmaceuticals Co., Ltd. Anticancer Biologics Revenue, Gross Margin and Market Share (2021-2026)
11.26.4 Jiangsu Alphamab Biopharmaceuticals Co., Ltd. Main Business Overview
11.26.5 Jiangsu Alphamab Biopharmaceuticals Co., Ltd. Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Anticancer Biologics Market Size CAGR by Region (2021 VS 2025 VS 2032) & ($ millions)
Table 2. Anticancer Biologics Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Antibody Therapies
Table 4. Major Players of Antibody-Drug Conjugates (ADCs)
Table 5. Major Players of Cell Therapies
Table 6. Major Players of Cancer Vaccines and Oncolytic Viruses
Table 7. Major Players of Others
Table 8. Anticancer Biologics Market Size CAGR by Type (2021 VS 2025 VS 2032) & ($ millions)
Table 9. Global Anticancer Biologics Market Size by Type (2021-2026) & ($ millions)
Table 10. Global Anticancer Biologics Market Size Market Share by Type (2021-2026)
Table 11. Major Players of Immune Checkpoint Targets
Table 12. Major Players of Solid Tumor-Associated Targets
Table 13. Major Players of Hematologic Tumor Targets
Table 14. Major Players of Angiogenesis-Related Targets
Table 15. Major Players of Others
Table 16. Anticancer Biologics Market Size CAGR by Target (2021 VS 2025 VS 2032) & ($ millions)
Table 17. Global Anticancer Biologics Market Size by Target (2021-2026) & ($ millions)
Table 18. Global Anticancer Biologics Market Size Market Share by Target (2021-2026)
Table 19. Major Players of Intravenous Administration
Table 20. Major Players of Subcutaneous Administration
Table 21. Major Players of Cell Infusion
Table 22. Major Players of Intratumoral Administration
Table 23. Major Players of Others
Table 24. Anticancer Biologics Market Size CAGR by Route of Administration (2021 VS 2025 VS 2032) & ($ millions)
Table 25. Global Anticancer Biologics Market Size by Route of Administration (2021-2026) & ($ millions)
Table 26. Global Anticancer Biologics Market Size Market Share by Route of Administration (2021-2026)
Table 27. Anticancer Biologics Market Size CAGR by Application (2021 VS 2025 VS 2032) & ($ millions)
Table 28. Global Anticancer Biologics Market Size by Application (2021-2026) & ($ millions)
Table 29. Global Anticancer Biologics Market Size Market Share by Application (2021-2026)
Table 30. Global Anticancer Biologics Revenue by Player (2021-2026) & ($ millions)
Table 31. Global Anticancer Biologics Revenue Market Share by Player (2021-2026)
Table 32. Anticancer Biologics Key Players Head office and Products Offered
Table 33. Anticancer Biologics Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 34. New Products and Potential Entrants
Table 35. Mergers & Acquisitions, Expansion
Table 36. Global Anticancer Biologics Market Size by Region (2021-2026) & ($ millions)
Table 37. Global Anticancer Biologics Market Size Market Share by Region (2021-2026)
Table 38. Global Anticancer Biologics Revenue by Country/Region (2021-2026) & ($ millions)
Table 39. Global Anticancer Biologics Revenue Market Share by Country/Region (2021-2026)
Table 40. Americas Anticancer Biologics Market Size by Country (2021-2026) & ($ millions)
Table 41. Americas Anticancer Biologics Market Size Market Share by Country (2021-2026)
Table 42. Americas Anticancer Biologics Market Size by Type (2021-2026) & ($ millions)
Table 43. Americas Anticancer Biologics Market Size Market Share by Type (2021-2026)
Table 44. Americas Anticancer Biologics Market Size by Application (2021-2026) & ($ millions)
Table 45. Americas Anticancer Biologics Market Size Market Share by Application (2021-2026)
Table 46. APAC Anticancer Biologics Market Size by Region (2021-2026) & ($ millions)
Table 47. APAC Anticancer Biologics Market Size Market Share by Region (2021-2026)
Table 48. APAC Anticancer Biologics Market Size by Type (2021-2026) & ($ millions)
Table 49. APAC Anticancer Biologics Market Size by Application (2021-2026) & ($ millions)
Table 50. Europe Anticancer Biologics Market Size by Country (2021-2026) & ($ millions)
Table 51. Europe Anticancer Biologics Market Size Market Share by Country (2021-2026)
Table 52. Europe Anticancer Biologics Market Size by Type (2021-2026) & ($ millions)
Table 53. Europe Anticancer Biologics Market Size by Application (2021-2026) & ($ millions)
Table 54. Middle East & Africa Anticancer Biologics Market Size by Region (2021-2026) & ($ millions)
Table 55. Middle East & Africa Anticancer Biologics Market Size by Type (2021-2026) & ($ millions)
Table 56. Middle East & Africa Anticancer Biologics Market Size by Application (2021-2026) & ($ millions)
Table 57. Key Market Drivers & Growth Opportunities of Anticancer Biologics
Table 58. Key Market Challenges & Risks of Anticancer Biologics
Table 59. Key Industry Trends of Anticancer Biologics
Table 60. Global Anticancer Biologics Market Size Forecast by Region (2027-2032) & ($ millions)
Table 61. Global Anticancer Biologics Market Size Market Share Forecast by Region (2027-2032)
Table 62. Global Anticancer Biologics Market Size Forecast by Type (2027-2032) & ($ millions)
Table 63. Global Anticancer Biologics Market Size Forecast by Application (2027-2032) & ($ millions)
Table 64. AbbVie Inc. Details, Company Type, Anticancer Biologics Area Served and Its Competitors
Table 65. AbbVie Inc. Anticancer Biologics Product Offered
Table 66. AbbVie Inc. Anticancer Biologics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 67. AbbVie Inc. Main Business
Table 68. AbbVie Inc. Latest Developments
Table 69. Johnson & Johnson Details, Company Type, Anticancer Biologics Area Served and Its Competitors
Table 70. Johnson & Johnson Anticancer Biologics Product Offered
Table 71. Johnson & Johnson Anticancer Biologics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 72. Johnson & Johnson Main Business
Table 73. Johnson & Johnson Latest Developments
Table 74. Novartis AG Details, Company Type, Anticancer Biologics Area Served and Its Competitors
Table 75. Novartis AG Anticancer Biologics Product Offered
Table 76. Novartis AG Anticancer Biologics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 77. Novartis AG Main Business
Table 78. Novartis AG Latest Developments
Table 79. Gilead Sciences, Inc. Details, Company Type, Anticancer Biologics Area Served and Its Competitors
Table 80. Gilead Sciences, Inc. Anticancer Biologics Product Offered
Table 81. Gilead Sciences, Inc. Anticancer Biologics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 82. Gilead Sciences, Inc. Main Business
Table 83. Gilead Sciences, Inc. Latest Developments
Table 84. Roche Holding AG Details, Company Type, Anticancer Biologics Area Served and Its Competitors
Table 85. Roche Holding AG Anticancer Biologics Product Offered
Table 86. Roche Holding AG Anticancer Biologics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 87. Roche Holding AG Main Business
Table 88. Roche Holding AG Latest Developments
Table 89. Bristol-Myers Squibb Company Details, Company Type, Anticancer Biologics Area Served and Its Competitors
Table 90. Bristol-Myers Squibb Company Anticancer Biologics Product Offered
Table 91. Bristol-Myers Squibb Company Anticancer Biologics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 92. Bristol-Myers Squibb Company Main Business
Table 93. Bristol-Myers Squibb Company Latest Developments
Table 94. Amgen Inc. Details, Company Type, Anticancer Biologics Area Served and Its Competitors
Table 95. Amgen Inc. Anticancer Biologics Product Offered
Table 96. Amgen Inc. Anticancer Biologics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 97. Amgen Inc. Main Business
Table 98. Amgen Inc. Latest Developments
Table 99. AstraZeneca plc Details, Company Type, Anticancer Biologics Area Served and Its Competitors
Table 100. AstraZeneca plc Anticancer Biologics Product Offered
Table 101. AstraZeneca plc Anticancer Biologics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 102. AstraZeneca plc Main Business
Table 103. AstraZeneca plc Latest Developments
Table 104. Merck & Co., Inc. Details, Company Type, Anticancer Biologics Area Served and Its Competitors
Table 105. Merck & Co., Inc. Anticancer Biologics Product Offered
Table 106. Merck & Co., Inc. Anticancer Biologics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 107. Merck & Co., Inc. Main Business
Table 108. Merck & Co., Inc. Latest Developments
Table 109. Takeda Pharmaceutical Company Limited Details, Company Type, Anticancer Biologics Area Served and Its Competitors
Table 110. Takeda Pharmaceutical Company Limited Anticancer Biologics Product Offered
Table 111. Takeda Pharmaceutical Company Limited Anticancer Biologics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 112. Takeda Pharmaceutical Company Limited Main Business
Table 113. Takeda Pharmaceutical Company Limited Latest Developments
Table 114. Merck KGaA Details, Company Type, Anticancer Biologics Area Served and Its Competitors
Table 115. Merck KGaA Anticancer Biologics Product Offered
Table 116. Merck KGaA Anticancer Biologics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 117. Merck KGaA Main Business
Table 118. Merck KGaA Latest Developments
Table 119. Eli Lilly and Company Details, Company Type, Anticancer Biologics Area Served and Its Competitors
Table 120. Eli Lilly and Company Anticancer Biologics Product Offered
Table 121. Eli Lilly and Company Anticancer Biologics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 122. Eli Lilly and Company Main Business
Table 123. Eli Lilly and Company Latest Developments
Table 124. Ono Pharmaceutical Co., Ltd. Details, Company Type, Anticancer Biologics Area Served and Its Competitors
Table 125. Ono Pharmaceutical Co., Ltd. Anticancer Biologics Product Offered
Table 126. Ono Pharmaceutical Co., Ltd. Anticancer Biologics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 127. Ono Pharmaceutical Co., Ltd. Main Business
Table 128. Ono Pharmaceutical Co., Ltd. Latest Developments
Table 129. Pfizer Inc. Details, Company Type, Anticancer Biologics Area Served and Its Competitors
Table 130. Pfizer Inc. Anticancer Biologics Product Offered
Table 131. Pfizer Inc. Anticancer Biologics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 132. Pfizer Inc. Main Business
Table 133. Pfizer Inc. Latest Developments
Table 134. GSK plc Details, Company Type, Anticancer Biologics Area Served and Its Competitors
Table 135. GSK plc Anticancer Biologics Product Offered
Table 136. GSK plc Anticancer Biologics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 137. GSK plc Main Business
Table 138. GSK plc Latest Developments
Table 139. Regeneron Pharmaceuticals, Inc. Details, Company Type, Anticancer Biologics Area Served and Its Competitors
Table 140. Regeneron Pharmaceuticals, Inc. Anticancer Biologics Product Offered
Table 141. Regeneron Pharmaceuticals, Inc. Anticancer Biologics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 142. Regeneron Pharmaceuticals, Inc. Main Business
Table 143. Regeneron Pharmaceuticals, Inc. Latest Developments
Table 144. Innovent Biologics, Inc. Details, Company Type, Anticancer Biologics Area Served and Its Competitors
Table 145. Innovent Biologics, Inc. Anticancer Biologics Product Offered
Table 146. Innovent Biologics, Inc. Anticancer Biologics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 147. Innovent Biologics, Inc. Main Business
Table 148. Innovent Biologics, Inc. Latest Developments
Table 149. Jiangsu Hengrui Pharmaceuticals Co., Ltd. Details, Company Type, Anticancer Biologics Area Served and Its Competitors
Table 150. Jiangsu Hengrui Pharmaceuticals Co., Ltd. Anticancer Biologics Product Offered
Table 151. Jiangsu Hengrui Pharmaceuticals Co., Ltd. Anticancer Biologics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 152. Jiangsu Hengrui Pharmaceuticals Co., Ltd. Main Business
Table 153. Jiangsu Hengrui Pharmaceuticals Co., Ltd. Latest Developments
Table 154. Shanghai Junshi Biosciences Co., Ltd. Details, Company Type, Anticancer Biologics Area Served and Its Competitors
Table 155. Shanghai Junshi Biosciences Co., Ltd. Anticancer Biologics Product Offered
Table 156. Shanghai Junshi Biosciences Co., Ltd. Anticancer Biologics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 157. Shanghai Junshi Biosciences Co., Ltd. Main Business
Table 158. Shanghai Junshi Biosciences Co., Ltd. Latest Developments
Table 159. Akeso, Inc. Details, Company Type, Anticancer Biologics Area Served and Its Competitors
Table 160. Akeso, Inc. Anticancer Biologics Product Offered
Table 161. Akeso, Inc. Anticancer Biologics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 162. Akeso, Inc. Main Business
Table 163. Akeso, Inc. Latest Developments
Table 164. Shanghai Henlius Biotech, Inc. Details, Company Type, Anticancer Biologics Area Served and Its Competitors
Table 165. Shanghai Henlius Biotech, Inc. Anticancer Biologics Product Offered
Table 166. Shanghai Henlius Biotech, Inc. Anticancer Biologics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 167. Shanghai Henlius Biotech, Inc. Main Business
Table 168. Shanghai Henlius Biotech, Inc. Latest Developments
Table 169. RemeGen Co., Ltd. Details, Company Type, Anticancer Biologics Area Served and Its Competitors
Table 170. RemeGen Co., Ltd. Anticancer Biologics Product Offered
Table 171. RemeGen Co., Ltd. Anticancer Biologics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 172. RemeGen Co., Ltd. Main Business
Table 173. RemeGen Co., Ltd. Latest Developments
Table 174. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Details, Company Type, Anticancer Biologics Area Served and Its Competitors
Table 175. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Anticancer Biologics Product Offered
Table 176. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Anticancer Biologics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 177. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Main Business
Table 178. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Latest Developments
Table 179. Sino Biopharmaceutical Limited Details, Company Type, Anticancer Biologics Area Served and Its Competitors
Table 180. Sino Biopharmaceutical Limited Anticancer Biologics Product Offered
Table 181. Sino Biopharmaceutical Limited Anticancer Biologics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 182. Sino Biopharmaceutical Limited Main Business
Table 183. Sino Biopharmaceutical Limited Latest Developments
Table 184. Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. Details, Company Type, Anticancer Biologics Area Served and Its Competitors
Table 185. Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. Anticancer Biologics Product Offered
Table 186. Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. Anticancer Biologics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 187. Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. Main Business
Table 188. Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. Latest Developments
Table 189. Jiangsu Alphamab Biopharmaceuticals Co., Ltd. Details, Company Type, Anticancer Biologics Area Served and Its Competitors
Table 190. Jiangsu Alphamab Biopharmaceuticals Co., Ltd. Anticancer Biologics Product Offered
Table 191. Jiangsu Alphamab Biopharmaceuticals Co., Ltd. Anticancer Biologics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 192. Jiangsu Alphamab Biopharmaceuticals Co., Ltd. Main Business
Table 193. Jiangsu Alphamab Biopharmaceuticals Co., Ltd. Latest Developments
Table 1. Anticancer Biologics Market Size CAGR by Region (2021 VS 2025 VS 2032) & ($ millions)
Table 2. Anticancer Biologics Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Antibody Therapies
Table 4. Major Players of Antibody-Drug Conjugates (ADCs)
Table 5. Major Players of Cell Therapies
Table 6. Major Players of Cancer Vaccines and Oncolytic Viruses
Table 7. Major Players of Others
Table 8. Anticancer Biologics Market Size CAGR by Type (2021 VS 2025 VS 2032) & ($ millions)
Table 9. Global Anticancer Biologics Market Size by Type (2021-2026) & ($ millions)
Table 10. Global Anticancer Biologics Market Size Market Share by Type (2021-2026)
Table 11. Major Players of Immune Checkpoint Targets
Table 12. Major Players of Solid Tumor-Associated Targets
Table 13. Major Players of Hematologic Tumor Targets
Table 14. Major Players of Angiogenesis-Related Targets
Table 15. Major Players of Others
Table 16. Anticancer Biologics Market Size CAGR by Target (2021 VS 2025 VS 2032) & ($ millions)
Table 17. Global Anticancer Biologics Market Size by Target (2021-2026) & ($ millions)
Table 18. Global Anticancer Biologics Market Size Market Share by Target (2021-2026)
Table 19. Major Players of Intravenous Administration
Table 20. Major Players of Subcutaneous Administration
Table 21. Major Players of Cell Infusion
Table 22. Major Players of Intratumoral Administration
Table 23. Major Players of Others
Table 24. Anticancer Biologics Market Size CAGR by Route of Administration (2021 VS 2025 VS 2032) & ($ millions)
Table 25. Global Anticancer Biologics Market Size by Route of Administration (2021-2026) & ($ millions)
Table 26. Global Anticancer Biologics Market Size Market Share by Route of Administration (2021-2026)
Table 27. Anticancer Biologics Market Size CAGR by Application (2021 VS 2025 VS 2032) & ($ millions)
Table 28. Global Anticancer Biologics Market Size by Application (2021-2026) & ($ millions)
Table 29. Global Anticancer Biologics Market Size Market Share by Application (2021-2026)
Table 30. Global Anticancer Biologics Revenue by Player (2021-2026) & ($ millions)
Table 31. Global Anticancer Biologics Revenue Market Share by Player (2021-2026)
Table 32. Anticancer Biologics Key Players Head office and Products Offered
Table 33. Anticancer Biologics Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 34. New Products and Potential Entrants
Table 35. Mergers & Acquisitions, Expansion
Table 36. Global Anticancer Biologics Market Size by Region (2021-2026) & ($ millions)
Table 37. Global Anticancer Biologics Market Size Market Share by Region (2021-2026)
Table 38. Global Anticancer Biologics Revenue by Country/Region (2021-2026) & ($ millions)
Table 39. Global Anticancer Biologics Revenue Market Share by Country/Region (2021-2026)
Table 40. Americas Anticancer Biologics Market Size by Country (2021-2026) & ($ millions)
Table 41. Americas Anticancer Biologics Market Size Market Share by Country (2021-2026)
Table 42. Americas Anticancer Biologics Market Size by Type (2021-2026) & ($ millions)
Table 43. Americas Anticancer Biologics Market Size Market Share by Type (2021-2026)
Table 44. Americas Anticancer Biologics Market Size by Application (2021-2026) & ($ millions)
Table 45. Americas Anticancer Biologics Market Size Market Share by Application (2021-2026)
Table 46. APAC Anticancer Biologics Market Size by Region (2021-2026) & ($ millions)
Table 47. APAC Anticancer Biologics Market Size Market Share by Region (2021-2026)
Table 48. APAC Anticancer Biologics Market Size by Type (2021-2026) & ($ millions)
Table 49. APAC Anticancer Biologics Market Size by Application (2021-2026) & ($ millions)
Table 50. Europe Anticancer Biologics Market Size by Country (2021-2026) & ($ millions)
Table 51. Europe Anticancer Biologics Market Size Market Share by Country (2021-2026)
Table 52. Europe Anticancer Biologics Market Size by Type (2021-2026) & ($ millions)
Table 53. Europe Anticancer Biologics Market Size by Application (2021-2026) & ($ millions)
Table 54. Middle East & Africa Anticancer Biologics Market Size by Region (2021-2026) & ($ millions)
Table 55. Middle East & Africa Anticancer Biologics Market Size by Type (2021-2026) & ($ millions)
Table 56. Middle East & Africa Anticancer Biologics Market Size by Application (2021-2026) & ($ millions)
Table 57. Key Market Drivers & Growth Opportunities of Anticancer Biologics
Table 58. Key Market Challenges & Risks of Anticancer Biologics
Table 59. Key Industry Trends of Anticancer Biologics
Table 60. Global Anticancer Biologics Market Size Forecast by Region (2027-2032) & ($ millions)
Table 61. Global Anticancer Biologics Market Size Market Share Forecast by Region (2027-2032)
Table 62. Global Anticancer Biologics Market Size Forecast by Type (2027-2032) & ($ millions)
Table 63. Global Anticancer Biologics Market Size Forecast by Application (2027-2032) & ($ millions)
Table 64. AbbVie Inc. Details, Company Type, Anticancer Biologics Area Served and Its Competitors
Table 65. AbbVie Inc. Anticancer Biologics Product Offered
Table 66. AbbVie Inc. Anticancer Biologics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 67. AbbVie Inc. Main Business
Table 68. AbbVie Inc. Latest Developments
Table 69. Johnson & Johnson Details, Company Type, Anticancer Biologics Area Served and Its Competitors
Table 70. Johnson & Johnson Anticancer Biologics Product Offered
Table 71. Johnson & Johnson Anticancer Biologics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 72. Johnson & Johnson Main Business
Table 73. Johnson & Johnson Latest Developments
Table 74. Novartis AG Details, Company Type, Anticancer Biologics Area Served and Its Competitors
Table 75. Novartis AG Anticancer Biologics Product Offered
Table 76. Novartis AG Anticancer Biologics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 77. Novartis AG Main Business
Table 78. Novartis AG Latest Developments
Table 79. Gilead Sciences, Inc. Details, Company Type, Anticancer Biologics Area Served and Its Competitors
Table 80. Gilead Sciences, Inc. Anticancer Biologics Product Offered
Table 81. Gilead Sciences, Inc. Anticancer Biologics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 82. Gilead Sciences, Inc. Main Business
Table 83. Gilead Sciences, Inc. Latest Developments
Table 84. Roche Holding AG Details, Company Type, Anticancer Biologics Area Served and Its Competitors
Table 85. Roche Holding AG Anticancer Biologics Product Offered
Table 86. Roche Holding AG Anticancer Biologics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 87. Roche Holding AG Main Business
Table 88. Roche Holding AG Latest Developments
Table 89. Bristol-Myers Squibb Company Details, Company Type, Anticancer Biologics Area Served and Its Competitors
Table 90. Bristol-Myers Squibb Company Anticancer Biologics Product Offered
Table 91. Bristol-Myers Squibb Company Anticancer Biologics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 92. Bristol-Myers Squibb Company Main Business
Table 93. Bristol-Myers Squibb Company Latest Developments
Table 94. Amgen Inc. Details, Company Type, Anticancer Biologics Area Served and Its Competitors
Table 95. Amgen Inc. Anticancer Biologics Product Offered
Table 96. Amgen Inc. Anticancer Biologics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 97. Amgen Inc. Main Business
Table 98. Amgen Inc. Latest Developments
Table 99. AstraZeneca plc Details, Company Type, Anticancer Biologics Area Served and Its Competitors
Table 100. AstraZeneca plc Anticancer Biologics Product Offered
Table 101. AstraZeneca plc Anticancer Biologics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 102. AstraZeneca plc Main Business
Table 103. AstraZeneca plc Latest Developments
Table 104. Merck & Co., Inc. Details, Company Type, Anticancer Biologics Area Served and Its Competitors
Table 105. Merck & Co., Inc. Anticancer Biologics Product Offered
Table 106. Merck & Co., Inc. Anticancer Biologics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 107. Merck & Co., Inc. Main Business
Table 108. Merck & Co., Inc. Latest Developments
Table 109. Takeda Pharmaceutical Company Limited Details, Company Type, Anticancer Biologics Area Served and Its Competitors
Table 110. Takeda Pharmaceutical Company Limited Anticancer Biologics Product Offered
Table 111. Takeda Pharmaceutical Company Limited Anticancer Biologics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 112. Takeda Pharmaceutical Company Limited Main Business
Table 113. Takeda Pharmaceutical Company Limited Latest Developments
Table 114. Merck KGaA Details, Company Type, Anticancer Biologics Area Served and Its Competitors
Table 115. Merck KGaA Anticancer Biologics Product Offered
Table 116. Merck KGaA Anticancer Biologics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 117. Merck KGaA Main Business
Table 118. Merck KGaA Latest Developments
Table 119. Eli Lilly and Company Details, Company Type, Anticancer Biologics Area Served and Its Competitors
Table 120. Eli Lilly and Company Anticancer Biologics Product Offered
Table 121. Eli Lilly and Company Anticancer Biologics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 122. Eli Lilly and Company Main Business
Table 123. Eli Lilly and Company Latest Developments
Table 124. Ono Pharmaceutical Co., Ltd. Details, Company Type, Anticancer Biologics Area Served and Its Competitors
Table 125. Ono Pharmaceutical Co., Ltd. Anticancer Biologics Product Offered
Table 126. Ono Pharmaceutical Co., Ltd. Anticancer Biologics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 127. Ono Pharmaceutical Co., Ltd. Main Business
Table 128. Ono Pharmaceutical Co., Ltd. Latest Developments
Table 129. Pfizer Inc. Details, Company Type, Anticancer Biologics Area Served and Its Competitors
Table 130. Pfizer Inc. Anticancer Biologics Product Offered
Table 131. Pfizer Inc. Anticancer Biologics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 132. Pfizer Inc. Main Business
Table 133. Pfizer Inc. Latest Developments
Table 134. GSK plc Details, Company Type, Anticancer Biologics Area Served and Its Competitors
Table 135. GSK plc Anticancer Biologics Product Offered
Table 136. GSK plc Anticancer Biologics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 137. GSK plc Main Business
Table 138. GSK plc Latest Developments
Table 139. Regeneron Pharmaceuticals, Inc. Details, Company Type, Anticancer Biologics Area Served and Its Competitors
Table 140. Regeneron Pharmaceuticals, Inc. Anticancer Biologics Product Offered
Table 141. Regeneron Pharmaceuticals, Inc. Anticancer Biologics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 142. Regeneron Pharmaceuticals, Inc. Main Business
Table 143. Regeneron Pharmaceuticals, Inc. Latest Developments
Table 144. Innovent Biologics, Inc. Details, Company Type, Anticancer Biologics Area Served and Its Competitors
Table 145. Innovent Biologics, Inc. Anticancer Biologics Product Offered
Table 146. Innovent Biologics, Inc. Anticancer Biologics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 147. Innovent Biologics, Inc. Main Business
Table 148. Innovent Biologics, Inc. Latest Developments
Table 149. Jiangsu Hengrui Pharmaceuticals Co., Ltd. Details, Company Type, Anticancer Biologics Area Served and Its Competitors
Table 150. Jiangsu Hengrui Pharmaceuticals Co., Ltd. Anticancer Biologics Product Offered
Table 151. Jiangsu Hengrui Pharmaceuticals Co., Ltd. Anticancer Biologics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 152. Jiangsu Hengrui Pharmaceuticals Co., Ltd. Main Business
Table 153. Jiangsu Hengrui Pharmaceuticals Co., Ltd. Latest Developments
Table 154. Shanghai Junshi Biosciences Co., Ltd. Details, Company Type, Anticancer Biologics Area Served and Its Competitors
Table 155. Shanghai Junshi Biosciences Co., Ltd. Anticancer Biologics Product Offered
Table 156. Shanghai Junshi Biosciences Co., Ltd. Anticancer Biologics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 157. Shanghai Junshi Biosciences Co., Ltd. Main Business
Table 158. Shanghai Junshi Biosciences Co., Ltd. Latest Developments
Table 159. Akeso, Inc. Details, Company Type, Anticancer Biologics Area Served and Its Competitors
Table 160. Akeso, Inc. Anticancer Biologics Product Offered
Table 161. Akeso, Inc. Anticancer Biologics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 162. Akeso, Inc. Main Business
Table 163. Akeso, Inc. Latest Developments
Table 164. Shanghai Henlius Biotech, Inc. Details, Company Type, Anticancer Biologics Area Served and Its Competitors
Table 165. Shanghai Henlius Biotech, Inc. Anticancer Biologics Product Offered
Table 166. Shanghai Henlius Biotech, Inc. Anticancer Biologics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 167. Shanghai Henlius Biotech, Inc. Main Business
Table 168. Shanghai Henlius Biotech, Inc. Latest Developments
Table 169. RemeGen Co., Ltd. Details, Company Type, Anticancer Biologics Area Served and Its Competitors
Table 170. RemeGen Co., Ltd. Anticancer Biologics Product Offered
Table 171. RemeGen Co., Ltd. Anticancer Biologics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 172. RemeGen Co., Ltd. Main Business
Table 173. RemeGen Co., Ltd. Latest Developments
Table 174. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Details, Company Type, Anticancer Biologics Area Served and Its Competitors
Table 175. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Anticancer Biologics Product Offered
Table 176. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Anticancer Biologics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 177. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Main Business
Table 178. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Latest Developments
Table 179. Sino Biopharmaceutical Limited Details, Company Type, Anticancer Biologics Area Served and Its Competitors
Table 180. Sino Biopharmaceutical Limited Anticancer Biologics Product Offered
Table 181. Sino Biopharmaceutical Limited Anticancer Biologics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 182. Sino Biopharmaceutical Limited Main Business
Table 183. Sino Biopharmaceutical Limited Latest Developments
Table 184. Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. Details, Company Type, Anticancer Biologics Area Served and Its Competitors
Table 185. Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. Anticancer Biologics Product Offered
Table 186. Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. Anticancer Biologics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 187. Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. Main Business
Table 188. Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. Latest Developments
Table 189. Jiangsu Alphamab Biopharmaceuticals Co., Ltd. Details, Company Type, Anticancer Biologics Area Served and Its Competitors
Table 190. Jiangsu Alphamab Biopharmaceuticals Co., Ltd. Anticancer Biologics Product Offered
Table 191. Jiangsu Alphamab Biopharmaceuticals Co., Ltd. Anticancer Biologics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 192. Jiangsu Alphamab Biopharmaceuticals Co., Ltd. Main Business
Table 193. Jiangsu Alphamab Biopharmaceuticals Co., Ltd. Latest Developments
LIST OF FIGURES
Figure 1. Anticancer Biologics Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Anticancer Biologics Market Size Growth Rate (2021-2032) ($ millions)
Figure 6. Anticancer Biologics Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 7. Anticancer Biologics Sales Market Share by Country/Region (2025)
Figure 8. Anticancer Biologics Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 9. Global Anticancer Biologics Market Size Market Share by Type in 2025
Figure 10. Global Anticancer Biologics Market Size Market Share by Target in 2025
Figure 11. Global Anticancer Biologics Market Size Market Share by Route of Administration in 2025
Figure 12. Anticancer Biologics in Lung Cancer
Figure 13. Global Anticancer Biologics Market: Lung Cancer (2021-2026) & ($ millions)
Figure 14. Anticancer Biologics in Breast Cancer
Figure 15. Global Anticancer Biologics Market: Breast Cancer (2021-2026) & ($ millions)
Figure 16. Anticancer Biologics in Hematologic Cancers
Figure 17. Global Anticancer Biologics Market: Hematologic Cancers (2021-2026) & ($ millions)
Figure 18. Anticancer Biologics in Gastrointestinal Cancers
Figure 19. Global Anticancer Biologics Market: Gastrointestinal Cancers (2021-2026) & ($ millions)
Figure 20. Anticancer Biologics in Others
Figure 21. Global Anticancer Biologics Market: Others (2021-2026) & ($ millions)
Figure 22. Global Anticancer Biologics Market Size Market Share by Application in 2025
Figure 23. Global Anticancer Biologics Revenue Market Share by Player in 2025
Figure 24. Global Anticancer Biologics Market Size Market Share by Region (2021-2026)
Figure 25. Americas Anticancer Biologics Market Size 2021-2026 ($ millions)
Figure 26. APAC Anticancer Biologics Market Size 2021-2026 ($ millions)
Figure 27. Europe Anticancer Biologics Market Size 2021-2026 ($ millions)
Figure 28. Middle East & Africa Anticancer Biologics Market Size 2021-2026 ($ millions)
Figure 29. Americas Anticancer Biologics Value Market Share by Country in 2025
Figure 30. United States Anticancer Biologics Market Size Growth 2021-2026 ($ millions)
Figure 31. Canada Anticancer Biologics Market Size Growth 2021-2026 ($ millions)
Figure 32. Mexico Anticancer Biologics Market Size Growth 2021-2026 ($ millions)
Figure 33. Brazil Anticancer Biologics Market Size Growth 2021-2026 ($ millions)
Figure 34. APAC Anticancer Biologics Market Size Market Share by Region in 2025
Figure 35. APAC Anticancer Biologics Market Size Market Share by Type (2021-2026)
Figure 36. APAC Anticancer Biologics Market Size Market Share by Application (2021-2026)
Figure 37. China Anticancer Biologics Market Size Growth 2021-2026 ($ millions)
Figure 38. Japan Anticancer Biologics Market Size Growth 2021-2026 ($ millions)
Figure 39. South Korea Anticancer Biologics Market Size Growth 2021-2026 ($ millions)
Figure 40. Southeast Asia Anticancer Biologics Market Size Growth 2021-2026 ($ millions)
Figure 41. India Anticancer Biologics Market Size Growth 2021-2026 ($ millions)
Figure 42. Australia Anticancer Biologics Market Size Growth 2021-2026 ($ millions)
Figure 43. Europe Anticancer Biologics Market Size Market Share by Country in 2025
Figure 44. Europe Anticancer Biologics Market Size Market Share by Type (2021-2026)
Figure 45. Europe Anticancer Biologics Market Size Market Share by Application (2021-2026)
Figure 46. Germany Anticancer Biologics Market Size Growth 2021-2026 ($ millions)
Figure 47. France Anticancer Biologics Market Size Growth 2021-2026 ($ millions)
Figure 48. UK Anticancer Biologics Market Size Growth 2021-2026 ($ millions)
Figure 49. Italy Anticancer Biologics Market Size Growth 2021-2026 ($ millions)
Figure 50. Russia Anticancer Biologics Market Size Growth 2021-2026 ($ millions)
Figure 51. Middle East & Africa Anticancer Biologics Market Size Market Share by Region (2021-2026)
Figure 52. Middle East & Africa Anticancer Biologics Market Size Market Share by Type (2021-2026)
Figure 53. Middle East & Africa Anticancer Biologics Market Size Market Share by Application (2021-2026)
Figure 54. Egypt Anticancer Biologics Market Size Growth 2021-2026 ($ millions)
Figure 55. South Africa Anticancer Biologics Market Size Growth 2021-2026 ($ millions)
Figure 56. Israel Anticancer Biologics Market Size Growth 2021-2026 ($ millions)
Figure 57. Turkey Anticancer Biologics Market Size Growth 2021-2026 ($ millions)
Figure 58. GCC Countries Anticancer Biologics Market Size Growth 2021-2026 ($ millions)
Figure 59. Americas Anticancer Biologics Market Size 2027-2032 ($ millions)
Figure 60. APAC Anticancer Biologics Market Size 2027-2032 ($ millions)
Figure 61. Europe Anticancer Biologics Market Size 2027-2032 ($ millions)
Figure 62. Middle East & Africa Anticancer Biologics Market Size 2027-2032 ($ millions)
Figure 63. United States Anticancer Biologics Market Size 2027-2032 ($ millions)
Figure 64. Canada Anticancer Biologics Market Size 2027-2032 ($ millions)
Figure 65. Mexico Anticancer Biologics Market Size 2027-2032 ($ millions)
Figure 66. Brazil Anticancer Biologics Market Size 2027-2032 ($ millions)
Figure 67. China Anticancer Biologics Market Size 2027-2032 ($ millions)
Figure 68. Japan Anticancer Biologics Market Size 2027-2032 ($ millions)
Figure 69. Korea Anticancer Biologics Market Size 2027-2032 ($ millions)
Figure 70. Southeast Asia Anticancer Biologics Market Size 2027-2032 ($ millions)
Figure 71. India Anticancer Biologics Market Size 2027-2032 ($ millions)
Figure 72. Australia Anticancer Biologics Market Size 2027-2032 ($ millions)
Figure 73. Germany Anticancer Biologics Market Size 2027-2032 ($ millions)
Figure 74. France Anticancer Biologics Market Size 2027-2032 ($ millions)
Figure 75. UK Anticancer Biologics Market Size 2027-2032 ($ millions)
Figure 76. Italy Anticancer Biologics Market Size 2027-2032 ($ millions)
Figure 77. Russia Anticancer Biologics Market Size 2027-2032 ($ millions)
Figure 78. Egypt Anticancer Biologics Market Size 2027-2032 ($ millions)
Figure 79. South Africa Anticancer Biologics Market Size 2027-2032 ($ millions)
Figure 80. Israel Anticancer Biologics Market Size 2027-2032 ($ millions)
Figure 81. Turkey Anticancer Biologics Market Size 2027-2032 ($ millions)
Figure 82. Global Anticancer Biologics Market Size Market Share Forecast by Type (2027-2032)
Figure 83. Global Anticancer Biologics Market Size Market Share Forecast by Application (2027-2032)
Figure 84. GCC Countries Anticancer Biologics Market Size 2027-2032 ($ millions)
Figure 1. Anticancer Biologics Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Anticancer Biologics Market Size Growth Rate (2021-2032) ($ millions)
Figure 6. Anticancer Biologics Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 7. Anticancer Biologics Sales Market Share by Country/Region (2025)
Figure 8. Anticancer Biologics Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 9. Global Anticancer Biologics Market Size Market Share by Type in 2025
Figure 10. Global Anticancer Biologics Market Size Market Share by Target in 2025
Figure 11. Global Anticancer Biologics Market Size Market Share by Route of Administration in 2025
Figure 12. Anticancer Biologics in Lung Cancer
Figure 13. Global Anticancer Biologics Market: Lung Cancer (2021-2026) & ($ millions)
Figure 14. Anticancer Biologics in Breast Cancer
Figure 15. Global Anticancer Biologics Market: Breast Cancer (2021-2026) & ($ millions)
Figure 16. Anticancer Biologics in Hematologic Cancers
Figure 17. Global Anticancer Biologics Market: Hematologic Cancers (2021-2026) & ($ millions)
Figure 18. Anticancer Biologics in Gastrointestinal Cancers
Figure 19. Global Anticancer Biologics Market: Gastrointestinal Cancers (2021-2026) & ($ millions)
Figure 20. Anticancer Biologics in Others
Figure 21. Global Anticancer Biologics Market: Others (2021-2026) & ($ millions)
Figure 22. Global Anticancer Biologics Market Size Market Share by Application in 2025
Figure 23. Global Anticancer Biologics Revenue Market Share by Player in 2025
Figure 24. Global Anticancer Biologics Market Size Market Share by Region (2021-2026)
Figure 25. Americas Anticancer Biologics Market Size 2021-2026 ($ millions)
Figure 26. APAC Anticancer Biologics Market Size 2021-2026 ($ millions)
Figure 27. Europe Anticancer Biologics Market Size 2021-2026 ($ millions)
Figure 28. Middle East & Africa Anticancer Biologics Market Size 2021-2026 ($ millions)
Figure 29. Americas Anticancer Biologics Value Market Share by Country in 2025
Figure 30. United States Anticancer Biologics Market Size Growth 2021-2026 ($ millions)
Figure 31. Canada Anticancer Biologics Market Size Growth 2021-2026 ($ millions)
Figure 32. Mexico Anticancer Biologics Market Size Growth 2021-2026 ($ millions)
Figure 33. Brazil Anticancer Biologics Market Size Growth 2021-2026 ($ millions)
Figure 34. APAC Anticancer Biologics Market Size Market Share by Region in 2025
Figure 35. APAC Anticancer Biologics Market Size Market Share by Type (2021-2026)
Figure 36. APAC Anticancer Biologics Market Size Market Share by Application (2021-2026)
Figure 37. China Anticancer Biologics Market Size Growth 2021-2026 ($ millions)
Figure 38. Japan Anticancer Biologics Market Size Growth 2021-2026 ($ millions)
Figure 39. South Korea Anticancer Biologics Market Size Growth 2021-2026 ($ millions)
Figure 40. Southeast Asia Anticancer Biologics Market Size Growth 2021-2026 ($ millions)
Figure 41. India Anticancer Biologics Market Size Growth 2021-2026 ($ millions)
Figure 42. Australia Anticancer Biologics Market Size Growth 2021-2026 ($ millions)
Figure 43. Europe Anticancer Biologics Market Size Market Share by Country in 2025
Figure 44. Europe Anticancer Biologics Market Size Market Share by Type (2021-2026)
Figure 45. Europe Anticancer Biologics Market Size Market Share by Application (2021-2026)
Figure 46. Germany Anticancer Biologics Market Size Growth 2021-2026 ($ millions)
Figure 47. France Anticancer Biologics Market Size Growth 2021-2026 ($ millions)
Figure 48. UK Anticancer Biologics Market Size Growth 2021-2026 ($ millions)
Figure 49. Italy Anticancer Biologics Market Size Growth 2021-2026 ($ millions)
Figure 50. Russia Anticancer Biologics Market Size Growth 2021-2026 ($ millions)
Figure 51. Middle East & Africa Anticancer Biologics Market Size Market Share by Region (2021-2026)
Figure 52. Middle East & Africa Anticancer Biologics Market Size Market Share by Type (2021-2026)
Figure 53. Middle East & Africa Anticancer Biologics Market Size Market Share by Application (2021-2026)
Figure 54. Egypt Anticancer Biologics Market Size Growth 2021-2026 ($ millions)
Figure 55. South Africa Anticancer Biologics Market Size Growth 2021-2026 ($ millions)
Figure 56. Israel Anticancer Biologics Market Size Growth 2021-2026 ($ millions)
Figure 57. Turkey Anticancer Biologics Market Size Growth 2021-2026 ($ millions)
Figure 58. GCC Countries Anticancer Biologics Market Size Growth 2021-2026 ($ millions)
Figure 59. Americas Anticancer Biologics Market Size 2027-2032 ($ millions)
Figure 60. APAC Anticancer Biologics Market Size 2027-2032 ($ millions)
Figure 61. Europe Anticancer Biologics Market Size 2027-2032 ($ millions)
Figure 62. Middle East & Africa Anticancer Biologics Market Size 2027-2032 ($ millions)
Figure 63. United States Anticancer Biologics Market Size 2027-2032 ($ millions)
Figure 64. Canada Anticancer Biologics Market Size 2027-2032 ($ millions)
Figure 65. Mexico Anticancer Biologics Market Size 2027-2032 ($ millions)
Figure 66. Brazil Anticancer Biologics Market Size 2027-2032 ($ millions)
Figure 67. China Anticancer Biologics Market Size 2027-2032 ($ millions)
Figure 68. Japan Anticancer Biologics Market Size 2027-2032 ($ millions)
Figure 69. Korea Anticancer Biologics Market Size 2027-2032 ($ millions)
Figure 70. Southeast Asia Anticancer Biologics Market Size 2027-2032 ($ millions)
Figure 71. India Anticancer Biologics Market Size 2027-2032 ($ millions)
Figure 72. Australia Anticancer Biologics Market Size 2027-2032 ($ millions)
Figure 73. Germany Anticancer Biologics Market Size 2027-2032 ($ millions)
Figure 74. France Anticancer Biologics Market Size 2027-2032 ($ millions)
Figure 75. UK Anticancer Biologics Market Size 2027-2032 ($ millions)
Figure 76. Italy Anticancer Biologics Market Size 2027-2032 ($ millions)
Figure 77. Russia Anticancer Biologics Market Size 2027-2032 ($ millions)
Figure 78. Egypt Anticancer Biologics Market Size 2027-2032 ($ millions)
Figure 79. South Africa Anticancer Biologics Market Size 2027-2032 ($ millions)
Figure 80. Israel Anticancer Biologics Market Size 2027-2032 ($ millions)
Figure 81. Turkey Anticancer Biologics Market Size 2027-2032 ($ millions)
Figure 82. Global Anticancer Biologics Market Size Market Share Forecast by Type (2027-2032)
Figure 83. Global Anticancer Biologics Market Size Market Share Forecast by Application (2027-2032)
Figure 84. GCC Countries Anticancer Biologics Market Size 2027-2032 ($ millions)
